Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease and Transplantation, Liver Disease Diagnosis and Treatment, Hepatitis C virus research, and Liver Diseases and Immunity.
Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome.
Factors Associated With Progression, Resolution and Mortality of Patients With Overt Hepatic Encephalopathy.
Assessment of sarcopenia in cirrhosis: A practical approach using thigh and psoas ultrasound, bioimpedance, and anthropometry.
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study.
Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease
Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease.
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.
Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.
The effects of elafibranor in people with primary biliary cholangitis: a plain language summary
PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study.
Genetic map of Wilson disease in Spain - A great tool to improve diagnosis and screening.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis
Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis
Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections-Results from the ICA "Global Study" (EABCIR-Global Study).
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis.
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study.
Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis.
Prophylactic antibiotics in patients with alcohol-associated hepatitis receiving steroids: A systematic review and meta-analysis.
Frailty and sarcopenia in patients with acute-on-chronic liver failure: Assessment and risk in the liver transplant setting.
Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.
Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design.
Development and external validation of a model to predict multidrug-resistant bacterial infections in patients with cirrhosis.
Bacterial Infection Features in Alcohol-Associated Hepatitis: Review of a 2016-2021 Cohort.
Bacterial Infections Features in Alcohol-Associated Hepatitis: Review of a 2016–2021 Cohort
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study